Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/0008-5472.CAN-14-3511 http://scihub22266oqcxt.onion/10.1158/0008-5472.CAN-14-3511 C4522159!4522159!25858148     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Res 2015 ; 75 (11): 2232-42 Nephropedia Template TP {{tp|p=25858148|t=2015. TGF? is a master regulator of radiation therapy-induced anti-tumor immunity |pdf=|usr=}}{{25858148}} gab.com Text TGF is a master regulator of radiation therapy-induced anti-tumor immunity JO: Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25858148 #FOAvip T cells directed to endogenous tumor antigens are powerful mediators of tumor regression. Recent immunotherapy advances have identified effective interventions to unleash tumor-specific T cell activity in patients who naturally develop them. Eliciting T cell responses to a patient's individual tumor remains a major challenge. Radiation therapy can induce immune responses to model antigens expressed by tumors, but it remains unclear if it can effectively prime T cells specific for endogenous antigens expressed by poorly immunogenic tumors. We hypothesized that TGF? activity is a major obstacle hindering the ability of radiation to generate an in situ tumor vaccine. Here we show that antibody-mediated TGF? neutralization during radiation therapy effectively generates CD8+ T cell responses to multiple endogenous tumor antigens in poorly immunogenic mouse carcinomas. Generated T cells were effective at causing regression of irradiated tumors and non-irradiated lung metastases or synchronous tumors (abscopal effect). Gene signatures associated with IFN? and immune-mediated rejection were detected in tumors treated with radiation therapy and TGF? blockade in combination but not as single agents. Upregulation of programmed death (PD) ligand-1 and -2 in neoplastic and myeloid cells and PD-1 on intratumoral T cells limited tumor rejection resulting in rapid recurrence. Addition of anti-PD-1 antibodies extended survival achieved with radiation and TGF? blockade. Thus, TGF? is a fundamental regulator of radiation therapy ability to generate an in situ tumor vaccine. The combination of local radiation therapy with TGF? neutralization offers a novel individualized strategy for vaccinating patients against their tumors. Twit Text FOAVip TGF is a master regulator of radiation therapy-induced anti-tumor immunity ????Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=25858148 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25858148 #FOAvip English Wikipedia <ref>{{Cite pmid|25858148}}</ref> TGF? is a master regulator of radiation therapy-induced anti-tumor immunity #MMPMID25858148 Vanpouille-Box C; Diamond JM; Pilones KA; Zavadil J; Babb JS; Formenti SC; Barcellos-Hoff MH; Demaria S Cancer Res 2015[Jun]; 75 (11): 2232-42 PMID25858148show ga T cells directed to endogenous tumor antigens are powerful mediators of tumor regression. Recent immunotherapy advances have identified effective interventions to unleash tumor-specific T cell activity in patients who naturally develop them. Eliciting T cell responses to a patient's individual tumor remains a major challenge. Radiation therapy can induce immune responses to model antigens expressed by tumors, but it remains unclear if it can effectively prime T cells specific for endogenous antigens expressed by poorly immunogenic tumors. We hypothesized that TGF? activity is a major obstacle hindering the ability of radiation to generate an in situ tumor vaccine. Here we show that antibody-mediated TGF? neutralization during radiation therapy effectively generates CD8+ T cell responses to multiple endogenous tumor antigens in poorly immunogenic mouse carcinomas. Generated T cells were effective at causing regression of irradiated tumors and non-irradiated lung metastases or synchronous tumors (abscopal effect). Gene signatures associated with IFN? and immune-mediated rejection were detected in tumors treated with radiation therapy and TGF? blockade in combination but not as single agents. Upregulation of programmed death (PD) ligand-1 and -2 in neoplastic and myeloid cells and PD-1 on intratumoral T cells limited tumor rejection resulting in rapid recurrence. Addition of anti-PD-1 antibodies extended survival achieved with radiation and TGF? blockade. Thus, TGF? is a fundamental regulator of radiation therapy ability to generate an in situ tumor vaccine. The combination of local radiation therapy with TGF? neutralization offers a novel individualized strategy for vaccinating patients against their tumors. äTGF? is a master regulator of radiation therapy-induced anti-tumor imm(epmc).pdf DeepDyve Pubget Overpricing